GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
about
A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413Organic carbamates in drug design and medicinal chemistryA novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.Highly resistant HIV-1 proteases and strategies for their inhibition.Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray StudiesBlood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDSGRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease
P2860
Q27728053-1A959477-EFF6-42F2-BCED-C081F999D818Q35365543-7E91609D-F3CF-4860-A9E4-783ECE2E84CBQ35386013-AB9DEEA7-E7CE-465B-88BE-56B54929BFC4Q35569236-20E46B62-B8CD-4F74-BDF8-E8B0A6B87365Q35907004-D98A07A0-C180-426F-8376-021F2A2C00D8Q35909838-7A8C69BD-8187-450B-A69A-B6D19FC8C45EQ36613697-4950468C-5E86-4336-A752-08CBF84378C0Q38267318-4417983B-F5DC-4FFB-8A19-A642A57E1C45Q38708006-71E9C801-3CBF-4593-A8BD-7AB73839AC32Q41930312-48F79DAD-47AA-4358-8651-E74128D409DEQ55432495-FDED61DB-6F6B-43D5-BC39-4333FC3A2017Q57063482-12956697-0495-4926-A06E-DA45F5EC896F
P2860
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GRL-04810 and GRL-05010, diflu ...... ood-brain barrier penetration.
@en
GRL-04810 and GRL-05010, diflu ...... ood-brain barrier penetration.
@nl
type
label
GRL-04810 and GRL-05010, diflu ...... ood-brain barrier penetration.
@en
GRL-04810 and GRL-05010, diflu ...... ood-brain barrier penetration.
@nl
prefLabel
GRL-04810 and GRL-05010, diflu ...... ood-brain barrier penetration.
@en
GRL-04810 and GRL-05010, diflu ...... ood-brain barrier penetration.
@nl
P2093
P2860
P356
P1476
GRL-04810 and GRL-05010, diflu ...... lood-brain barrier penetration
@en
P2093
Akira Mizuno
Arun K Ghosh
Debananda Das
Hiroaki Mitsuya
Pedro Miguel Salcedo Gómez
Sofiya Yashchuk
P2860
P304
P356
10.1128/AAC.01420-13
P407
P577
2013-09-30T00:00:00Z